Literature DB >> 20347111

An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.

Adi Moseri1, Subramanyam Tantry, Yael Sagi, Boris Arshava, Fred Naider, Jacob Anglister.   

Abstract

Synthetic peptides offer an attractive option for development of a V3-directed vaccine. However, immunization with flexible linear peptides may result in an immune response to multiple conformations, many of which differ from the native conformation of the corresponding region in the protein. Here we show that optimization of the location of a disulfide bond in peptides constrained to mimic the beta-hairpin conformation of the V3, yields an immunogen that elicits a 30-fold stronger HIV-1 neutralizing response in rabbits compared with the homologous linear V3 peptide. The HIV-1 neutralizing response elicited by the optimally constrained peptide is also significantly stronger than that elicited by a gp120 construct in which the V3 is exposed. Neutralization of an HIV-1 strain that shares only 72% identity with the immunizing peptide was demonstrated. The most effective immunogen was also able to neutralize primary isolates that are more resistant to neutralization such as SS1196 and 6535. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347111      PMCID: PMC2862131          DOI: 10.1016/j.virol.2010.03.007

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  40 in total

1.  Solution conformation of a peptide corresponding to the principal neutralizing determinant of HIV-1IIIB: a two-dimensional NMR study.

Authors:  A Zvi; R Hiller; J Anglister
Journal:  Biochemistry       Date:  1992-08-04       Impact factor: 3.162

2.  Improved immunogenicity of HIV-1 epitopes in HBsAg chimeric DNA vaccine plasmids by structural mutations of HBsAg.

Authors:  K Bryder; H Sbai; H V Nielsen; S Corbet; C Nielsen; R G Whalen; A Fomsgaard
Journal:  DNA Cell Biol       Date:  1999-03       Impact factor: 3.311

3.  Cyclic V3-loop-related HIV-1 conjugate vaccines. Synthesis, conformation and immunological properties.

Authors:  R L Tolman; M A Bednarek; B A Johnson; W J Leanza; S Marburg; D J Underwood; E A Emini; A J Conley
Journal:  Int J Pept Protein Res       Date:  1993-05

4.  Identification of HIV vaccine candidate peptides by screening random phage epitope libraries.

Authors:  P M Keller; B A Arnold; A R Shaw; R L Tolman; F Van Middlesworth; S Bondy; V K Rusiecki; S Koenig; S Zolla-Pazner; P Conard
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

5.  A helical epitope in the C4 domain of HIV glycoprotein 120.

Authors:  F A Robey; T Kelson-Harris; P P Roller; M Robert-Guroff
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

6.  Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens.

Authors:  A J Conley; P Conard; S Bondy; C A Dolan; J Hannah; W J Leanza; S Marburg; M Rivetna; V K Rusiecki; E E Sugg
Journal:  Vaccine       Date:  1994-04       Impact factor: 3.641

7.  Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins.

Authors:  J D Fontenot; J M Gatewood; S V Mariappan; C P Pau; B S Parekh; J R George; G Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-03       Impact factor: 11.205

8.  Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.

Authors:  Beverly E Sha; Michelle Onorato; John A Bartlett; Ronald J Bosch; Evgenia Aga; Mostafa Nokta; Elizabeth M Adams; Xiao-Dong Li; John Eldridge; Richard B Pollard
Journal:  AIDS       Date:  2004-05-21       Impact factor: 4.177

9.  Characterization of V3 loop-Pseudomonas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1.

Authors:  D J FitzGerald; C M Fryling; M L McKee; J C Vennari; T Wrin; M E Cromwell; A L Daugherty; R J Mrsny
Journal:  J Biol Chem       Date:  1998-04-17       Impact factor: 5.486

10.  A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein.

Authors:  Hanna C Kelker; Vincenza R Itri; Fred T Valentine
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more
  18 in total

1.  Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Authors:  Miroslaw K Gorny; Ruimin Pan; Constance Williams; Xiao-Hong Wang; Barbara Volsky; Timothy O'Neal; Brett Spurrier; Jared M Sampson; Liuzhe Li; Michael S Seaman; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Virology       Date:  2012-03-07       Impact factor: 3.616

2.  Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

Authors:  Ann J Hessell; Sean McBurney; Shilpi Pandey; William Sutton; Lily Liu; Liuzhe Li; Maxim Totrov; Susan Zolla-Pazner; Nancy L Haigwood; Miroslaw K Gorny
Journal:  Vaccine       Date:  2016-04-19       Impact factor: 3.641

3.  Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.

Authors:  Adi Moseri; Subramanyam Tantry; Fa-Xiang Ding; Fred Naider; Jacob Anglister
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-26       Impact factor: 2.205

4.  Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Authors:  Franco Pissani; Delphine C Malherbe; Harlan Robins; Victor R DeFilippis; Byung Park; George Sellhorn; Leonidas Stamatatos; Julie Overbaugh; Nancy L Haigwood
Journal:  Vaccine       Date:  2012-06-27       Impact factor: 3.641

5.  The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.

Authors:  Adi Moseri; Zohar Biron; Boris Arshava; Tali Scherf; Fred Naider; Jacob Anglister
Journal:  FEBS J       Date:  2015-10-22       Impact factor: 5.542

6.  Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope.

Authors:  Robyn L Stanfield; Jean-Philippe Julien; Robert Pejchal; Johannes S Gach; Michael B Zwick; Ian A Wilson
Journal:  J Mol Biol       Date:  2011-10-15       Impact factor: 5.469

Review 7.  Protein engineering strategies for the development of viral vaccines and immunotherapeutics.

Authors:  Jayne F Koellhoffer; Chelsea D Higgins; Jonathan R Lai
Journal:  FEBS Lett       Date:  2013-10-21       Impact factor: 4.124

8.  Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

Authors:  Susan Zolla-Pazner; X-P Kong; Xunqing Jiang; Timothy Cardozo; Arthur Nádas; Sandra Cohen; Maxim Totrov; Michael S Seaman; Shixia Wang; Shan Lu
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

9.  Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.

Authors:  Raiees Andrabi; Rajesh Kumar; Manju Bala; Ambili Nair; Ashutosh Biswas; Naveet Wig; Pratik Kumar; Rahul Pal; Subrata Sinha; Kalpana Luthra
Journal:  Virol J       Date:  2012-09-12       Impact factor: 4.099

Review 10.  Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology.

Authors:  John A Robinson
Journal:  J Pept Sci       Date:  2013-01-24       Impact factor: 1.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.